NCOA2
MOLECULAR TARGETNCOA2 protein (human)
NCOA2 (NCOA2 protein (human)) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NCOA2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Methylene Blue | 1.61 | 4 |
| 2 | urolithin b | 1.39 | 3 |
| 3 | Anisomycin | 1.10 | 2 |
| 4 | cycloheximide | 1.10 | 2 |
| 5 | Digoxin | 1.10 | 2 |
| 6 | Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, | 1.10 | 2 |
| 7 | Tubercidin | 1.10 | 2 |
| 8 | alsterpaullone | 0.69 | 1 |
| 9 | gedunin | 0.69 | 1 |
| 10 | Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide. | 0.69 | 1 |
| 11 | Thioridazine | 0.69 | 1 |
About NCOA2 as a Drug Target
NCOA2 (NCOA2 protein (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented NCOA2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NCOA2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.